Skip To Main Content
Keiko Nakajima on Muck Rack

Keiko Nakajima

As seen in: Annals of Oncology, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Keiko Nakajima’s profile

Articles by Keiko Nakajima

Sorafenib treatment by Child-Pugh score in Latin American patients with hepatocellular carcinoma

|
By Lucy Dagher, Vanessa MV Arruda, Keiko Nakajima, Masatoshi Kudo
| Future Medicine Verified
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second major cause of tumor-related death in the world [1,2].
Open in Who Shared Issue with article?

O3-13-4Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma

|
By Riccardo Lencioni, Masatoshi Kudo, Sheng-Long Ye, Keiko Nakajima
| Annals of Oncology Verified
O3-13-4Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma Masatoshi Kudo1, Sheng-Long Ye2, Keiko Nakajima3 and Riccardo Lencioni4 1Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Higashiosaka City, Osaka, Japan 2Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China 3Global Medical Affairs, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA 4University of Miami...
Open in Who Shared Issue with article?
Show More